Novo Nordisk A/S (NYSE:NVO) Shares Purchased by International Assets Investment Management LLC

International Assets Investment Management LLC lifted its position in Novo Nordisk A/S (NYSE:NVO) by 69.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,420 shares of the company’s stock after purchasing an additional 5,496 shares during the period. International Assets Investment Management LLC’s holdings in Novo Nordisk A/S were worth $1,712,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in NVO. City State Bank increased its holdings in Novo Nordisk A/S by 769.2% in the 1st quarter. City State Bank now owns 1,130 shares of the company’s stock worth $145,000 after acquiring an additional 1,000 shares in the last quarter. &PARTNERS purchased a new stake in Novo Nordisk A/S in the 1st quarter worth $783,000. MJP Associates Inc. ADV increased its holdings in Novo Nordisk A/S by 15.0% in the 1st quarter. MJP Associates Inc. ADV now owns 4,465 shares of the company’s stock worth $573,000 after acquiring an additional 583 shares in the last quarter. David J Yvars Group increased its holdings in Novo Nordisk A/S by 10.2% in the 1st quarter. David J Yvars Group now owns 31,034 shares of the company’s stock worth $3,985,000 after acquiring an additional 2,862 shares in the last quarter. Finally, Bennett Selby Investments LP grew its holdings in shares of Novo Nordisk A/S by 2.1% during the first quarter. Bennett Selby Investments LP now owns 22,483 shares of the company’s stock worth $2,887,000 after buying an additional 468 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on NVO shares. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a report on Thursday, May 30th. They set a “buy” rating and a $156.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Monday, June 17th. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Finally, Argus upped their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $145.67.

Novo Nordisk A/S Trading Up 0.7 %

NYSE NVO opened at $141.96 on Monday. The firm’s 50-day moving average is $132.94 and its two-hundred day moving average is $122.05. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $144.50. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The stock has a market capitalization of $637.05 billion, a P/E ratio of 48.95, a PEG ratio of 1.40 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The company had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. On average, sell-side analysts anticipate that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.